healthcaretechoutlook

Biomedical Sensors for the Future: Enabling Technologies at Homecare

By Healthcare Tech Outlook | Monday, November 26, 2018

Biosensors are playing a pivotal role in everyday life. As innovations in technology advances, the biomedical sensors can monitor many aspects of health at home. Here the question is, how close is this to the future and what are their impacts on the healthcare system? Biosensors recently started to be broadly marketed for wellness and fitness applications, and these devices are based on the detection of a specific molecule that is linked to a health condition and can offer actionable insights into what’s happening in the human body. The market for biosensors is proliferating. It is predicted to reach up to €22B by 2020, pushed by a wave of new technologies that are making them more accessible for both patients and consumers.

A plethora of biosensors is developed over the past decades for health organizations. At present, a point of care applications constitutes the largest use of biosensors. Neuro-monitoring system developed by a Swiss company Luciole Medical measures blood oxygen levels in the brain. However, home monitoring kits such as glucose monitors used by diabetic patients, are the fastest growing segment of the biosensor market. Self-monitoring with biosensors has the efficiency to impact the care of patients with virtually any chronic diseases, by changing the paradigm from monthly appointment to daily monitoring, helping anticipate side effects and prevent progression of a disease.

Home monitoring shows a huge impact in ensuring that patients comply with the treatment that is prescribed by a provider. The EU-funded study portrays that almost 200,000 deaths every year occur due to a missing dose or taking an incorrect dose.

Aripiprazole, a drug used for treating mental illness was recently approved by FDA. It is a digital pill that is developed by Otsuka pharmaceuticals to monitor the ingestion of the Aripiprazole drug.  Lucentix biosensor is used to measure the concentration levels of the drug in a drop of blood or saliva. Federal de Lausanne develops this biosensor. Some biosensors are incorporated into human tissue for continuous health monitoring of the humans. These devices are developed by U.S-based Profusa, and the device is implemented for real-time monitoring of tissue oxygen, which is applied in peripheral artery disease, COPD, diabetic ulcers, and reconstructive surgery. Only some of the innovations have been marketed, though the industry is rapidly advancing.

New Editions